All Programs

MMyeRisk: Defining Tumor and Immune Markers to Stratify Patients at Risk of Developing Multiple Myeloma from MGUS and Smoldering Myeloma

iRelate: Assessment of PET Tracers to Evaluate T Cell Change and Activation in Relation to Immunotherapy Treatment Response in Non-Small Cell Lung Cancer

Convening Experts in Oncology to Address Children’s Health (COACH)

Sallie Rosen Kaplan Fund for Women Scientists in Cancer Research

Overview In 2000, the estate of Sallie Rosen Kaplan established The Sallie Rosen Kaplan Postdoctoral Fellowship for Women Scientists in Ca...

Jayne Koskinas Ted Giovanis Foundation for Health Policy – Support for Intramural Research Training Fellows

Overview Since 2018, the Jayne Koskinas Ted Giovanis (JKTG) Foundation for Health and Policy has supported Intramural Research Training Awa...

International Liquid Biopsy Standardization Alliance (ILSA)

Overview The Foundation for the National Institutes of Health (FNIH) Biomarkers Consortium is a host and founding partner of the Internatio...

Dean R. O’Neill Renal Cell Cancer Research Fund

Overview Our Fund, the Dean R. O’Neill Renal Cell Cancer Research Fund, helps recruit the next generation of physician-scientists and cli...

Dr. Edward T. Rancic Memorial Fund for Cancer Research

Overview The Dr. Edward T. Rancic Memorial Fund provides support for a post-doctoral fellowship focused on renal cell cancer—the most com...

Dr. Anita Roberts Memorial Fund

Overview The Dr. Anita Roberts Memorial Fund awards travel scholarships for graduate students and post-doctoral fellows to present their wo...

Cancer Research Fund

The Cancer Research Fund enables individuals to support cancer research at the National Cancer Institute (NCI). Goals Enable individua...

Biomarkers Consortium – Vol-PACT Phase II: Advanced metrics and modeling with Volumetric CT for Precision Analysis of Clinical Trial results

The Problem The cancer research field lacks well-tested biomarkers to measure disease progression and to predict how patients respond to tr...

Biomarkers Consortium – Measurable residual disease in acute myeloid leukemia (MRD in AML)

Acute myeloid leukemia (AML) is a heterogeneous genetic disease. According to the National Cancer Institute (NCI), an estimated 20,240 new A...

Biomarkers Consortium – ctDNA Quality Control Materials Project

The Problem Tumor DNA circulating in bodily fluids offers researchers a valuable tool to study, and thus to treat, cancer. Yet the wide var...

Biomarkers Consortium – CSC Scientific Symposium

The Problem cancer research is a large and diverse field, making it difficult to coordinate efforts across its many subfields, which are fo...

Biomarkers Consortium – NiP-Metastatic Prostate Cancer

Overview Metastatic castration-resistant prostate cancer (mCRPC) is the second leading cause of cancer death of American men. Over 80% of t...

Biomarkers Consortium – I-SPY TRIAL-2 (Investigation of Serial Studies to Predict Your Therapeutic Response with Imaging and MoLecular Analysis): An Adaptive Breast Cancer Trial Design in the Setting of Neoadjuvant Chemotherapy

Overview The I-SPY 2 trial was setup to accelerate the pace of qualifying effective novel agents for breast cancer by testing new agents in...

Adam J. Berry Memorial Fund

Overview Since 2003, the Adam J. Berry Memorial Fund has supported travel for early-career Australian scientists to work at the NIH, in p...